Opinion
Video
Key RRMM-Related Takeaways from ASH 2023
Dr Fonesca provides his final thoughts recapping data and findings presented at ASH 2023.
This is a video synopsis/summary of a Post Conference Perspectives featuring Rafael Fonseca, MD.
An update was provided on sonrotoclax, a next-generation BCL2 inhibitor that may exceed venetoclax potency. Early data combining sonrotoclax and dexamethasone shows efficacy in relapsed/refractory multiple myeloma with a favorable toxicity profile. This is an exciting addition given challenges gaining regulatory approval for venetoclax despite its clear value. While this translocation in level 14 imperfectly predicts response, other biomarkers like BCL2 expression levels or BCL2/BCL2L1 ratios could identify responsive patients for BCL2 inhibition. Fonesca hopes sonrotoclax progresses to become the first FDA-approved drug in this class for myeloma.
Looking ahead, 2024 may reveal more around small molecules like BCL2 inhibitors and next-generation cereblon-binding agents. Earlier chimeric antigen receptor T-cell and bispecific antibody data could emerge, potentially transforming outcomes when combined. The recent promising data also warrants follow-up. Fonseca believes properly combining these modalities can achieve high minimal residual disease negativity rates and long-term disease control. While myeloma remains incurable, glimpses of potential cures are being seen that bring hope for the future.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
